NCT01594931View on ClinicalTrials.gov

Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria

PHASE2CompletedINTERVENTIONAL

Enrollment

477

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

March 31, 2006

Study Completion Date

April 30, 2006

Conditions

Plasmodium Falciparum Malaria

Interventions

DRUG

pyronaridine/artesunate

Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1. The tablets were taken daily for 3 days.

Trial Locations (6)

Unknown

Pailin General Hospital, Pailin

Bethesday Hospital, Tomohon

Centre de santé du roi Baudoin, Guédiawaye

Faculty of Tropical Medicine, Mahidol University, Bangkok

Farafenni Field Station, c/o MRC Laboratories, Farafenni

MSF Epicentre, Mbarara

All Listed Sponsors

collaborator

Shin Poong Pharmaceutical Co. Ltd.

INDUSTRY

lead

Medicines for Malaria Venture

OTHER

NCT01594931 - Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria | Biotech Hunter | Biotech Hunter